UBS Biotech Equity Fund has a track record back to 1996. The management company is UBS Asset Management, the asset management division of the listed Swiss banking group UBS Group, headquartered in Zürich. UBS completed its acquisition of Credit Suisse in 2023.
Investment philosophy
The managers state that they favour innovative small and mid-sized companies, especially those with platform technologies that can address multiple disease targets.
The managers
Matthew Konosky and Sarah Schram, both in Chicago, are listed on the fund. Konosky joined UBS in 2006, has managed the fund since 2017 and was previously a healthcare analyst at Sanford C. Bernstein. Schram is a biotechnology analyst with a PhD in neuroscience and has been a named co-manager since 2025, after working as a biotechnology analyst at William Blair. Charlotte Harris in London is also listed, and Pascal Mercier in Zürich was a named manager from 2025 to 2026. They are part of UBS's health care and biotech team, which draws on the healthcare analysts in the US intrinsic value equity team and also manages UBS Sustainable Health Transformation Equity Fund.
The portfolio
The portfolio is concentrated at the top, and the fund has fluctuated less than comparable funds. Steady positions include Vertex Pharmaceuticals, AbbVie, Amgen, Gilead Sciences, Ionis Pharmaceuticals, Insmed, Roivant Sciences and Guardant Health.
FundTelligence description · 18/10/2026
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
Industry Biotechnology Equities · 6 funds in the peer group. The number ranked and the date are stated per period. 3 of them converted to NOK.
2 of 4 funds ranked on a calculated return
#2/ 4Year to date
+19.70% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#1/ 41 year
+25.96% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#3/ 43 years (ann.)
+17.42% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
#3/ 45 years (ann.)
+9.96% NOK
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.
Comparison basis
Year to date
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
1 year
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
3 years (ann.)
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
5 years (ann.)
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026
The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.